These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12868147)

  • 21. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature.
    Sarıkaya S; Resorlu M; Oguz U; Yordam M; Bozkurt OF; Unsal A
    Arch Ital Urol Androl; 2014 Dec; 86(4):288-90. PubMed ID: 25641453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part I: pathology, digital rectal examination, transrectal ultrasound, and PSA].
    Rodríguez-Patrón Rodríguez R; Mayayo Dehesa T; Alonso González M; Burgos Revilla FJ; Lennie Zucharino A
    Arch Esp Urol; 2005 Sep; 58(7):611-22. PubMed ID: 16294783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Echo-guided transrectal biopsy. An analysis of the results in a series of 1900 patients].
    Mayayo Dehesa T; Rodríguez-Patrón R; Zuccarino AL; Arias Funez F; Carrera Puerta C; García González R
    Arch Esp Urol; 1999 Jun; 52(5):453-63. PubMed ID: 10427883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography].
    Isa Kroon WA; Robles JE; de Castro F; Rosell D; Abad JI; Zudaire JJ; Berián JM
    Actas Urol Esp; 1993 Jun; 17(6):341-5; discussion 345-6. PubMed ID: 7690176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of Histoscanning™ prior to prostate biopsy for the diagnosis of prostate adenocarcinoma.
    Núñez-Mora C; García-Mediero JM; Patiño P; Orellana C; Garrido A; Rojo A; Rendón D
    Actas Urol Esp; 2013 Jun; 37(6):342-6. PubMed ID: 23507291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Screening for prostatic carcinoma in dysuric patients: diagnostic protocols and cost-benefit analysis].
    Grasso Leanza F; Panella P; Pennisi M; Pepe P
    Arch Ital Urol Androl; 1997 Jun; 69(3):143-9. PubMed ID: 9273088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.
    Casciani E; Polettini E; Bertini L; Emiliozzi P; Amini M; Pansadoro V; Gualdi GF
    Radiol Med; 2004; 108(5-6):530-41. PubMed ID: 15722999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
    Tsui KH; Chang PL; Wang TM; Hsieh ML
    Changgeng Yi Xue Za Zhi; 1997 Mar; 20(1):23-8. PubMed ID: 9178589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Yield of transrectal ultrasonography in the diagnosis of prostatic cancer in symptomatic patients with normal rectal digital test].
    Herranz Amo F; Verdu Tartajo F; Diez Cordero JM; Sánchez Carreras F; Lledo García E; Bueno Chomon G; Leal Hernández F
    Actas Urol Esp; 1997 Jun; 21(6):565-71. PubMed ID: 9412190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels.
    Shim HB; Lee SE; Park HK; Ku JH
    Int Urol Nephrol; 2007; 39(4):1115-20. PubMed ID: 17610039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Systematic ultrasound guided transrectal core prostate biopsy based on serum level of prostate-specific antigen].
    Yamaguchi S; Baba Y; Naito K
    Hinyokika Kiyo; 1997 Sep; 43(9):641-5. PubMed ID: 9365843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.